Macrophages are immune cells that are supposed to protect the body from infection by viruses and bacteria. Yet Zika virus preferentially infects these cells. Researchers at University of California San Diego School of Medicine have now unraveled how the virus shuts down the genes that make macrophages function as immune cells.
The study is published the week of September 10 in
Proceedings of the National Academy of Sciences.
Neighboring infected and uninfected human macrophages during a Zika virus infection in a lab dish. Zika virus is labeled red; Macrophage nuclei are labeled blue.
In pregnant women, Zika virus can stunt neonatal brain development, leading to babies born with abnormally small heads, a condition known as microcephaly. Adult brain cells may also be vulnerable to the virus.
“We know Zika virus destroys a number of cell types, particularly in the brain, but we don’t yet understand how it causes cells to die or malfunction,” said first author Aaron Carlin, MD, PhD, associate physician at UC San Diego School of Medicine. “So this loss of general gene transcription and identity we saw in macrophages could also be crucial when a neural stem cell is trying to develop into a new neuron.”
Carlin led the study with Christopher K. Glass, MD, PhD, professor in the departments of Medicine and Cellular and Molecular Medicine at UC San Diego School of Medicine, and Sujan Shresta, PhD, professor at La Jolla Institute for Allergy and Immunology.
Carlin and team first developed a method for tagging the Zika virus inside live cells, and a mechanism for sorting tagged (infected) and untagged (uninfected) human macrophages. Many previous viral studies relied on dishes of cells that had been exposed to the virus, but not necessarily all cells were infected. As a result, the cellular effects measured in a laboratory “infection” are often a mixture of what’s going on inside both infected and uninfected cells.
“If your goal is to see what a virus is doing to a cell, you need to focus on only infected cells to get true representation,” Carlin said.
The difference they found with the new technique was startling.
“We were surprised at just how different infected and uninfected cells looked, in terms of the genes they had turned on or off, even two cells next to each other,” Glass said. “What’s amazing is that even though they are exposed to the same environment, their responses are completely different. And now we know those differences are truly due to the virus, not any of the other events going on around the cells during an immune response.”
This approach provided a more accurate account of Zika’s effect on macrophages and revealed that the virus suppressed gene production in the cells by two methods. First, the virus specifically blocks hundreds of macrophage genes that should be stimulated by interferon, a molecule that triggers an immune response. For example, the
IFITM1 gene, which inhibits Zika virus, is expressed 73-fold less in Zika-infected cells than in neighboring uninfected cells. Second, Zika infection leads to general suppression of gene production because the virus targets RNA Pol II, a crucial part of the cell’s gene transcription machinery. The loss of RNA Pol II is especially notable at genes responsible for macrophage function and identity.
Collectively, these approaches allow Zika virus to stop macrophages from making many genes involved in immune cell recruitment and anti-viral defense.
Moving forward, Carlin, Glass and team are interested in applying their new sorting technique to cells infected by other viruses. They also hope to examine other cell types infected by Zika virus, such as neural stem cells.
Additional study co-authors include: Edward A. Vizcarra, Emilie Branche, Karla M. Viramontes, La Jolla Institute for Allergy and Immunology; Lester Suarez-Amaran, Sven Heinz, and Chris Benner, UC San Diego.
This research was funded, in part, by the National Institutes of Health (R01DK091183, P01DK074868, R01AI116813, R21NS100477, R21AI127988, 1KL2TR001444), Kyowa Kirin Pharmaceutical Research and Burroughs Wellcome Fund.